explore -WSS

explore

author：hotspot 2025-10-01 11:00:11 - browse：5

A sign of Gilead Sciences sits in front of its headquarter and next to a pedestrian crossing sign — health coverage from STAT — Justin Sullivan/Getty Images

The assault on the development of new lifesaving therapies continues apace. Recently, the First Appellate Division of California Appeals held that companies not only have to defend products they have developed and marketed, but also those they have not.

In 2001, Gilead secured FDA approval of tenofovir disoproxil fumarate (TDF), one of first medicines to treat HIV — a product still on the market, despite the potential side effect of causing skeletal and kidney damage. In the years that followed, the company invested in research leading to additional TDF-based regimens critical to the fight against HIV. It had also done preliminary work on a similar but different drug — tenofovir alafenamide fumarate (TAF) — for which it had early, although not definitive, evidence for safety and efficacy.

Ultimately, this medicine was shown to have a better side effect profile than TDF. Starting in 2018, plaintiffs began suing Gilead for negligently failing to develop TAF earlier, on the theory that it wanted to protect the profits from TDF. Now, the California court has agreed to let the suit proceed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： National panel will explore requiring free Covid tests

WSS

The UK government moves asylum

Nearly a dozen Russian and Chinese ships now moving away from Alaska, officials say

NYC plans to house migrants on an island in the East River

Sage hopes for a blockbuster in antidepressant now before FDA

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

Israel demolishes home of alleged Palestinian attacker, fueling West Bank tensions

hotspot

explore

focus

Psychedelics group wrestles with new pharma identity

Illinois to ban advertising for guns allegedly marketed to kids and militants

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Micronoma's microbiome cancer diagnostic approach under fire

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Illinois to ban advertising for guns allegedly marketed to kids and militants

BioMarin wins approval for gene therapy to treat hemophilia A

3 dead in firefighting helicopter crash in California after midair collision with 2nd helicopter

How to save PrEP access — and even expand it

What to expect as Trump is arraigned on his Jan 6. indictment

focus

Teen said 'homophobic slurs' before O'Shae Sibley killing: Criminal complaint

‘Oppenheimer’ and the risks of AI in health care

In medicine, common shorthands can shortchange care

Judges halt a Biden rule offering student debt relief for those alleging colleges misled them

Appeals court upholds Josh Duggar's conviction for downloading child sex abuse images

3 dead in firefighting helicopter crash in California after midair collision with 2nd helicopter

focus

focus

leisure time

entertainment